Safety and Efficacy of AS-3201 in the Treatment of Diabetic Sensorimotor Polyneuropathy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with the following may enter:
Clinical signs and symptoms (footpain, numbness, tingling, weakness, etc.) of symmetrical distal Diabetic Sensorimotor Polyneuropathy with diagnosis by Nerve Conduction Tests and/or Quantitative Sensory Test.
18 to 70 years old of either sex and any race
Type I or Type II, insulin-dependent or non insulin-dependent diabetes for at least six months prior to study entry
Healthy in general
No hospitalizations for diabetic control or episodes of ketoacidosis for three months prior to screening
Female patients of childbearing potential must have a negative serum pregnancy test
Known non-diabetic causes of neuropathic symptoms
Diabetic patients with no neuropathy or severe neuropathy
Used any Aldose Reductase Inhibitors within one year of screening
Clinically significant illness including unstable cardiac, pulmonary, hematologic, hepatic, renal, or neoplastic disease
A history of systemic carcinoma within five years of screening
A history of epilepsy or serious head injury
A history or evidence of drug or alcohol abuse
Test positive at screening for hepatitis B surface antigen or hepatitis C antibody or have a history of a positive result, or patients with evidence of significant hepatic insufficiency
A history of known or suspected diagnosis of AIDS, or have tested seropositive for HIV antibody or antigen previously